IQVIA Holdings Inc. (NYSE:IQV) Holdings Decreased by Farallon Capital Management LLC

Farallon Capital Management LLC lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,123,151 shares of the medical research company’s stock after selling 47,932 shares during the quarter. IQVIA accounts for about 3.1% of Farallon Capital Management LLC’s holdings, making the stock its 7th biggest position. Farallon Capital Management LLC owned approximately 1.72% of IQVIA worth $613,730,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of IQVIA in the fourth quarter valued at approximately $336,041,000. Raymond James Financial Inc. bought a new stake in IQVIA in the fourth quarter valued at about $236,120,000. American Century Companies Inc. boosted its stake in IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after buying an additional 905,960 shares in the last quarter. Invesco Ltd. boosted its stake in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after purchasing an additional 902,226 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock valued at $841,461,000 after buying an additional 712,958 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on IQV shares. Barclays cut their price target on IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a report on Wednesday. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Citigroup lowered their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $231.71.

IQVIA Price Performance

Shares of IQV opened at $153.39 on Friday. The firm has a market capitalization of $27.04 billion, a PE ratio of 20.45, a PEG ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company’s 50-day moving average is $164.60 and its 200-day moving average is $189.07. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion during the quarter, compared to analysts’ expectations of $3.77 billion. During the same quarter in the previous year, the company posted $2.54 earnings per share. The business’s revenue was up 2.5% on a year-over-year basis. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.